Clinically proven doesn't mean what you think

Walk down any beauty aisle, or scroll any patient’s skincare app, and the phrase ‘clinically proven’ is everywhere. It might mean a molecule tested alone in a petridish. It might mean a consumer survey where people simply said their skin felt better. Or, more rarely, it might mean a randomised, blinded, controlled trial with objective biological endpoints. The phrase on the jar is identical every time. The evidence behind it is not.

For practitioners, that gap isn’t academic. Patients ask, point blank, whether something will work, and increasingly they’ve seen the same ASA advertising rulings you have. This year The Skin Diary launched Cell-to-Surface, a three-tier testing standard that requires every formula to clear independent testing at the cell, on the surface and in the mirror before any efficacy claim is published. Here’s what sits behind it, and why it changes what you
can say at the counter.

An evidence problem, not a marketing problem

“‘Clinically proven’ is widely used in skincare but can mean very little when it comes to evidence,” says Dr Clare Kiely, co-founder and chief medical officer of The Skin Diary, a Mohs surgeon and chair of the Cosmetic Practice Standards Authority. “Even as a dermatologist, when I read a surface-level clinical study I often can’t tell you whether a product is actually working or simply moisturising the skin. I see that same confusion in my patients every day.”

Ingredient innovation has never been more accessible, which is genuinely a good thing. But it also means a molecule can show a promising signal in a cell culture, acquire a compelling story, and reach the shelf as a ‘breakthrough’ before the finished formula has been tested at the concentration people actually use. Drug development teaches us that promising laboratory findings often don’t translate into real-world performance. The Skin Diary’s founders believe the same principle of final-formulation testing should apply to skincare.

A cell culture is not skin

“Testing an ingredient and testing a product are not the same exercise,” says Professor Chris Griffiths OBE, co-founder of The Skin Diary and a professor of dermatology whose research is among the most cited in the field. In 1993, Griffiths’s team published research showing that retinoic acid could measurably repair photoaged skin, a finding that shaped a career spent asking whether a finished formula, at the concentration people actually use, produces a real structural change in real skin. “A cell culture is not skin. A molecule is not a product. That distinction is the whole argument.”

That principle underpins the Manchester Patch Test Assay, the peer-reviewed biopsy method Griffiths co-developed, and now underpins Cell-to-Surface. In Manchester assay testing, Night Repair Therapy produced a two-fold increase in both fibrillin and collagen, the structural proteins skin loses to ageing and UV exposure, an effect equivalent to 20 times that of standard over-the-counter retinol, without the irritation associated with traditional retinoids. On the surface, the same formula reduced wrinkle volume over 12 weeks, with a significant reduction visible within seven days.

From the biopsy to the mirror

Biopsy data and instrument readings answer two of Cell-to-Surface’s three questions. The third is the one patients actually ask: does it work, on their face, in real life?

“I don’t lead with lab data when a patient asks if something will work. I lead with what I’ve seen,” says Julie Scott, The Skin Diary’s clinical lead, who has used and recommended the brand’s products in clinic for close to a year. Scott has just completed a 12-week in-clinic study of women aged 35 to 65 using Night Repair Therapy and Age Defence together, daily, tracking redness and sensitivity, radiance, tone, fine lines and barrier function alongside the cellular and surface data. “This is a chain of evidence, from the cell, to the surface, to the patient looking in the mirror. Not a claim. Not a story. That’s what gives me the confidence, as a practitioner, to recommend these products, not just reach for them.”

Early findings from Scott’s study point to calmer, less reactive skin, improved radiance and tone, and softer fine lines around the eyes, changes she links to the same fibrillin and collagen support demonstrated at the cellular level. Full results and patient imagery will follow in the coming weeks.

Why this matters at the counter

For practitioners recommending skincare alongside in-clinic treatment, the value of Cell-to-Surface isn’t only the data itself, it’s what it lets you say to a patient with confidence, and what it lets you ask of every other brand on your shelf. Both products below are validated end-to-end under the standard and are available now to UK-based Wigmore Medical account holders.

“It’s a standard, not a slogan,” Kiely says. “I hope it pushes the rest of the industry to raise its own bar too.” For practitioners fielding the same “does this actually work” question every day, that’s the point: evidence patients, and you, can actually stand behind.